Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -42.05% is in line with its 5-year average of -45.26%, near the high end of its 5-year range (-168.37%–-2.72%).
As of the fiscal period ended Monday, June 30, 2025. 28.36% below its 12-month average of -32.76%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-06-30.
RETURN ON EQUITY (ROE)
-42.05%
RETURN ON EQUITY (ROE) AVG TTM
-32.76%
RETURN ON EQUITY (ROE) AVG 3Y
-25.11%
RETURN ON EQUITY (ROE) AVG 5Y
-45.26%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-28.36%
CURRENT VS 3Y AVG
-67.43%
CURRENT VS 5Y AVG
+7.09%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-0.10%
vs the sector median at left
Gelteq Limited Ordinary Shares
Market Cap
$5.32M
Return on Equity (ROE)
-42.05%
TTM Avg
-32.76%
3Y Avg
-25.11%
5Y Avg
-45.26%
Market Cap
$5.31M
Return on Equity (ROE)
-154.08%
TTM Avg
-205.06%
3Y Avg
-23.78%
5Y Avg
-114.15%
Market Cap
$5.35M
Return on Equity (ROE)
-163.18%
TTM Avg
-235.11%
3Y Avg
-195.15%
5Y Avg
-161.13%
Market Cap
$5.24M
Return on Equity (ROE)
-225.57%
TTM Avg
-289.16%
3Y Avg
-245.03%
5Y Avg
-192.04%
Market Cap
$5.22M
Return on Equity (ROE)
-156.94%
TTM Avg
-121.17%
3Y Avg
-95.34%
5Y Avg
-84.55%
Market Cap
$5.21M
Return on Equity (ROE)
-248.66%
TTM Avg
-110.63%
3Y Avg
-33.84%
5Y Avg
-33.84%
Market Cap
$5.21M
Return on Equity (ROE)
-156.77%
TTM Avg
-655.11%
3Y Avg
-353.82%
5Y Avg
-293.10%
Market Cap
$5.12M
Return on Equity (ROE)
N/A
TTM Avg
383.38%
3Y Avg
131.31%
5Y Avg
101.98%
Market Cap
$5.63M
Return on Equity (ROE)
-92.08%
TTM Avg
-1221.97%
3Y Avg
-730.41%
5Y Avg
-532.44%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gelteq Limited Ordinary Shares (GELS) | $5.32M | -42.05% | -32.76% | -25.11% | -45.26% |
| Soligenix, Inc. (SNGX)vs › | $5.31M | -154.08% | -205.06% | -23.78% | -114.15% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | -163.18% | -235.11% | -195.15% | -161.13% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -225.57% | -289.16% | -245.03% | -192.04% |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | -156.94% | -121.17% | -95.34% | -84.55% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | -248.66% | -110.63% | -33.84% | -33.84% |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | -156.77% | -655.11% | -353.82% | -293.10% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | N/A | 383.38% | 131.31% | 101.98% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -92.08% | -1221.97% | -730.41% | -532.44% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | -4165.92% | 61.14% | -23.12% | -18.15% |
ROE
-42.0%
ROA
-30.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | -42.05% |
| 2024-06-30 | -23.47% |
| 2023-06-30 | -18.79% |
| 2022-06-30 | -16.15% |
| 2021-06-30 | -2.72% |
| 2020-06-30 | -168.37% |
